Phase 1 Kidney Cancer Trial, Recruiting NCT05433142 Sponsor: Xencor, Inc. Condition: Kidney Cancer
Back to Kidney Cancer

Phase 1 Kidney Cancer Trial, Recruiting

NCT05433142
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your cancer must have measurable tumors that can be tracked on scans, following a standard measurement system called RECIST 1.1 (even in areas that were previously treated with radiation, if the tumor has grown there).
  • You must have one of these cancers that has come back or stopped responding to standard treatments, and is still growing: clear cell kidney cancer (ccRCC), papillary kidney cancer (pRCC), non-small cell lung cancer (NSCLC), or colorectal cancer (CRC).
  • You must be in generally good physical condition, able to carry out normal daily activities with little or no limitation (rated 0 or 1 on a standard health scale).
  • A sample of your tumor tissue must be available for testing, either as slides or a stored tissue block.

Who may not be able to join:

  • You have previously been treated with an experimental therapy that targets a protein called ENPP3/CD203c.
  • You have had a serious or life-threatening allergic reaction to a type of drug called a monoclonal antibody.
  • You have received cancer treatment too recently before starting the trial (within a timeframe based on how long the previous treatment stays active in your body).
  • You have not yet recovered from significant side effects caused by a previous cancer treatment.
  • You currently have active cancer that has spread to the brain or the lining around the brain — though people whose brain metastases were previously treated and are now stable on scans may still be eligible (confirm with trial site).
  • You have an active autoimmune disease, with some exceptions — certain manageable conditions like vitiligo, type 1 diabetes, thyroid conditions treated with hormone replacement, mild skin conditions not requiring systemic treatment, or mild arthritis managed without systemic medicines may still be allowed (confirm with trial site).
  • You have had a serious infection requiring intravenous (IV) antibiotics or other IV treatments within the 14 days before starting the trial.
  • You have another cancer that is currently growing or has required active treatment within the last 2 years.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Xencor, Inc.
Registry
ClinicalTrials.gov
Start date
13 June 2022
Est. completion
1 February 2027

Where this trial is recruiting

🇧🇪 Belgium 🇫🇷 France 🇪🇸 Spain 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Incidence of treatment-emergent adverse events (safety and tolerability of XmAb819); Incidence of dose limiting toxicities (DLTs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov